A Phase 3 interventional study of inhaled treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-26.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Open-label extension of RIN-PH-302.
761 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →United Therapeutics is the lead sponsor of 81 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 14 (82%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participation and completion of all required visits for study RIN-PH-302.
Drug: inhaled treprostinil
0.6mg/mL inhalation solution, up to 12 breaths four times a day
Long term safety of inhaled treprostinil
Time frame: up to 5 years
Six-minute walk distance
Time frame: up to 5 years
No study locations are listed for this record.
This study is withdrawn, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Arterial Hypertension→
United Therapeutics